<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Alice T. Shaw et al.|Clinical Cancer Research|2016Cited by 1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Nir Peled et al.|New England Journal of Medicine|2020Cited by 835
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Justin F. Gainor et al.|Cancer Discovery|2018Cited by 392
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Justin F. Gainor, Matthew D. Hellmann et al.|Nature Genetics|2023Cited by 185